ownloade short circulating half-life and side effects of IFNα affect its dosing schedule and efficacy. Fusion of IFNα mor-targeting monoclonal antibody (MAb-IFNα) can enhance potency due to increased tumor localiand improved pharmacokinetics. We report the generation and characterization of the first bispecific FNα, designated 20-C2-2b, which comprises two copies of IFNα2b and a stabilized F(ab...

[1] Enger, P. O. et al. Hum.Gene Ther. 2002; 13: 1115–1125. [2] Kirn, D. et al. Nat.Med. 2001; 7: 781–787. [3] Haviv, Y. S. et al. Adv.Drug Deliv.Rev. 2001; 53: 135–154. [4] Siders, W. M. et al. Cancer Gene Ther. 1998; 5: 281–291. [5] Rots, M. G. et al. J.Control Release 2003; 87: 159–165. [6] Schaack, J. et al. Proc.Natl.Acad.Sci.U.S.A 1996; 93: 14686–14691. [7] Balzar, M. et al. J.Mol.Med. 19...